Acurx Pharmaceuticals

Founder‑led team with relevant antibiotic development and transaction experience (e.g., Dipexium) and meaningful insider ownership as of mid‑2025. The team has executed on regulatory milestones and scientific collaborations.

Nevertheless, the key test will be securing Phase 3 funding on acceptable terms and delivering pivotal data while managing dilution.